title: The first fifty consecutive Bentall operations with a prefabricated tissue-valved aortic conduit: a single-center experience.
abstract: OBJECTIVE
  Composite replacement is the standard treatment for the repair of aortic aneurysm with aortic valve pathology. With improved long-term durability and no requirement for long-term anticoagulation, tissue-valved conduits have become increasingly popular. Herein are reported the results achieved with 50 consecutive 'Bentall' operations, using the first commercially available prefabricated stentless tissue-valved conduit (Vascutek BioValsalva).
  
  
  METHODS
  Between September 2007 and September 2009, a total of 50 patients (10 females, 40 males; mean age 65 +/- 7 years) received a BioValsalva conduit. Concomitant procedures included coronary artery bypass grafting (CABG; n = 15), other valve (n = 5), and aortic arch replacement with circulatory arrest (n = 20; three of these had an additional frozen elephant trunk). Four of the procedures were re-operations. A six-month follow up with echocardiography and clinical examination was completed in 25 patients.
  
  
  RESULTS
  The 30-day mortality was 8% (4/50). Three of these patients underwent concomitant procedures. The cardiopulmonary bypass (CPB) and cross-clamp times were 178 +/- 30 min and 106 +/- 7 min, respectively. The triple-layered vascular graft proved to be hemostatic, without suture-line bleeding. Both, the initial and follow up echocardiography showed no valvular insufficiency, with a mean gradient of 13 +/- 5 mmHg. All patients were in NYHA class I-II.
  
  
  CONCLUSIONS
  The BioValsalva prefabricated tissue-valved conduit showed very good early results. The ischemic time required to construct a 'home-made' stentless tissue-valved conduit was eliminated, thus reducing the cross-clamp time. The conduit also offered the hemodynamic advantages of a stentless valve.
authors.affiliation: Department of Cardiothoracic, Transplantation, and Vascular Surgery, Hannover Medical School, Hannover, Germany.
authors.forename: Hassina
authors.initials: H
authors.lastname: Baraki
authors.forename: Ammar
authors.initials: A
authors.lastname: Al Ahmad
authors.forename: Samir
authors.initials: S
authors.lastname: Sarikouch
authors.forename: Nurbol
authors.initials: N
authors.lastname: Koigeldiev
authors.forename: Nawid
authors.initials: N
authors.lastname: Khaladj
authors.forename: Christian
authors.initials: C
authors.lastname: Hagl
authors.forename: Maximillian
authors.initials: M
authors.lastname: Pichlmaier
authors.forename: Axel
authors.initials: A
authors.lastname: Haverich
authors.forename: Malakh
authors.initials: M
authors.lastname: Shrestha
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001014:Aortic Aneurysm / Q000453:epidemiology / Q000601:surgery*; D001807:Blood Vessel Prosthesis; D019917:Blood Vessel Prosthesis Implantation; D015897:Comorbidity; D005260:Female; D006349:Heart Valve Diseases / Q000453:epidemiology / Q000601:surgery*; D006350:Heart Valve Prosthesis; D019918:Heart Valve Prosthesis Implantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D011474:Prosthesis Design